Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  Galena Biopharma Inc    GALE   US3632561086

 SummaryQuotesChart AnalysisNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/26/2015 01/27/2015 01/28/2015 01/29/2015 01/30/2015 Date
1.72(c) 1.71(c) 1.65(c) 1.63(c) 1.63(c) Last
769 802 755 625 1 483 853 748 608 655 632 Volume
+3.61% -0.58% -3.51% -1.21% 0.00% Change
More quotes
Company
Galena Biopharma, Inc. is a biotechnology company focused on discovering, developing and commercializing innovative, targeted oncology treatments that address major unmet medical needs to advance cancer care.It currently develops peptide antigenbased off the shelf cancer immunotherapies for... 
Sector
Pharmaceuticals
Calendar
02/10 | 11:00amPresentation
More about the company
Surperformance© ratings of Galena Biopharma Inc
Trading Rating : Investor Rating :
More Ratings
Chart GALENA BIOPHARMA INC
Duration : Period :
Galena Biopharma Inc Technical Analysis Chart | GALE | US3632561086 | 4-Traders
Full-screen chart
Financials ($)
Sales 2014 8,70 M
EBIT 2014 -53,2 M
Net income 2014 -44,5 M
Debt 2014 -
Yield 2014 -
Sales 2015 18,0 M
EBIT 2015 -42,4 M
Net income 2015 -41,9 M
Debt 2015 -
Yield 2015 -
PER 2014 -
PER 2015
Capi. / Sales 2014 22,8x
Capi. / Sales 2015 11,0x
Capitalization 198 M
More Financials
Latest news on GALENA BIOPHARMA INC
01/28 Galena Biopharma to Present at the 17th Annual BIO CEO & Investor Conference
01/20 GALENA BIOPHARMA : Hires Joseph Lasaga as Vice President, Business Development a..
01/15 Galena Biopharma to Present at the Noble Financial Capital Markets 11th Annua..
01/15 OREXO : Receives Paragraph IV Notice Letter Concerning Abstral® in the US
01/14 GALENA BIOPHARMA : Other Events (form 8-K)
01/08 Galena Biopharma Provides 2015 Outlook
2014 Galena Biopharma Presents HER2 Screening Data Including Preliminary Leica Bon..
2014 GALENA BIOPHARMA : Presents GALE-401 (Anagrelide Controlled Release) Clinical Tr..
More news
Sector news Pharmaceuticals - NEC
09:15a JOHNSON & JOHNSON : Former FDA chief calls J&J misleading on Risperdal
01/30 SANOFI : 72 HOUR DEADLINE ALERT: Approximately 72 Hours Remain; Former Louisiana..
01/30 ABBVIE : breakup with Shire torpedoes 4th quarter, 2014 results
Plus d'actualités du secteur Pharmaceuticals - NEC


Comments 
Advertisement
Technical analysis trends
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Technical analysis
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF